196 related articles for article (PubMed ID: 25098340)
1. Dual-inhibitors of STAT5 and STAT3: studies from molecular docking and molecular dynamics simulations.
Shao S; Yu R; Yu Y; Li Y
J Mol Model; 2014 Aug; 20(8):2399. PubMed ID: 25098340
[TBL] [Abstract][Full Text] [Related]
2. Cryptotanshinone suppresses key onco-proliferative and drug-resistant pathways of chronic myeloid leukemia by targeting STAT5 and STAT3 phosphorylation.
Dong B; Liang Z; Chen Z; Li B; Zheng L; Yang J; Zhou H; Qu L
Sci China Life Sci; 2018 Sep; 61(9):999-1009. PubMed ID: 30054832
[TBL] [Abstract][Full Text] [Related]
3. Combined targeting of STAT3 and STAT5: a novel approach to overcome drug resistance in chronic myeloid leukemia.
Gleixner KV; Schneeweiss M; Eisenwort G; Berger D; Herrmann H; Blatt K; Greiner G; Byrgazov K; Hoermann G; Konopleva M; Waliul I; Cumaraswamy AA; Gunning PT; Maeda H; Moriggl R; Deininger M; Lion T; Andreeff M; Valent P
Haematologica; 2017 Sep; 102(9):1519-1529. PubMed ID: 28596283
[TBL] [Abstract][Full Text] [Related]
4. The STAT5 inhibitor pimozide decreases survival of chronic myelogenous leukemia cells resistant to kinase inhibitors.
Nelson EA; Walker SR; Weisberg E; Bar-Natan M; Barrett R; Gashin LB; Terrell S; Klitgaard JL; Santo L; Addorio MR; Ebert BL; Griffin JD; Frank DA
Blood; 2011 Mar; 117(12):3421-9. PubMed ID: 21233313
[TBL] [Abstract][Full Text] [Related]
5. Exploring dual inhibitors for STAT1 and STAT5 receptors utilizing virtual screening and dynamics simulation validation.
Raj U; Kumar H; Gupta S; Varadwaj PK
J Biomol Struct Dyn; 2016 Oct; 34(10):2115-29. PubMed ID: 26471877
[TBL] [Abstract][Full Text] [Related]
6. Emodin Inhibits Resistance to Imatinib by Downregulation of Bcr-Abl and STAT5 and Allosteric Inhibition in Chronic Myeloid Leukemia Cells.
Wang XY; Sun GB; Wang YJ; Yan F
Biol Pharm Bull; 2020; 43(10):1526-1533. PubMed ID: 32999163
[TBL] [Abstract][Full Text] [Related]
7. Novel multiplexed assay for identifying SH2 domain antagonists of STAT family proteins.
Takakuma K; Ogo N; Uehara Y; Takahashi S; Miyoshi N; Asai A
PLoS One; 2013; 8(8):e71646. PubMed ID: 23977103
[TBL] [Abstract][Full Text] [Related]
8. Characterization of molecular recognition of STAT3 SH2 domain inhibitors through molecular simulation.
Park IH; Li C
J Mol Recognit; 2011; 24(2):254-65. PubMed ID: 21360612
[TBL] [Abstract][Full Text] [Related]
9. Alpha-Based Multiplexed Assay for Identifying SH2 Domain Antagonists.
Asai A; Takakuma K
Methods Mol Biol; 2017; 1555():351-356. PubMed ID: 28092042
[TBL] [Abstract][Full Text] [Related]
10. Novel STAT3 small-molecule inhibitors identified by structure-based virtual ligand screening incorporating SH2 domain flexibility.
Kong R; Bharadwaj U; Eckols TK; Kolosov M; Wu H; Cruz-Pavlovich FJS; Shaw A; Ifelayo OI; Zhao H; Kasembeli MM; Wong STC; Tweardy DJ
Pharmacol Res; 2021 Jul; 169():105637. PubMed ID: 33932608
[TBL] [Abstract][Full Text] [Related]
11. Screening of potent STAT3-SH2 domain inhibitors from JAK/STAT compound library through molecular dynamics simulation.
Manoharan S; Balakrishnan A; Hemamalini V; Perumal E
Mol Divers; 2023 Jun; 27(3):1297-1308. PubMed ID: 35831728
[TBL] [Abstract][Full Text] [Related]
12. An SH2 domain model of STAT5 in complex with phospho-peptides define "STAT5 Binding Signatures".
Gianti E; Zauhar RJ
J Comput Aided Mol Des; 2015 May; 29(5):451-70. PubMed ID: 25752764
[TBL] [Abstract][Full Text] [Related]
13. Selective Inhibition of STAT3 with Respect to STAT1: Insights from Molecular Dynamics and Ensemble Docking Simulations.
Yesylevskyy SO; Ramseyer C; Pudlo M; Pallandre JR; Borg C
J Chem Inf Model; 2016 Aug; 56(8):1588-96. PubMed ID: 27479469
[TBL] [Abstract][Full Text] [Related]
14. Identification of STAT1 and STAT3 specific inhibitors using comparative virtual screening and docking validation.
Szelag M; Czerwoniec A; Wesoly J; Bluyssen HA
PLoS One; 2015; 10(2):e0116688. PubMed ID: 25710482
[TBL] [Abstract][Full Text] [Related]
15. Development of Erasin: a chromone-based STAT3 inhibitor which induces apoptosis in Erlotinib-resistant lung cancer cells.
Lis C; Rubner S; Roatsch M; Berg A; Gilcrest T; Fu D; Nguyen E; Schmidt AM; Krautscheid H; Meiler J; Berg T
Sci Rep; 2017 Dec; 7(1):17390. PubMed ID: 29234062
[TBL] [Abstract][Full Text] [Related]
16. Dasatinib (BMS-354825) inhibits Stat5 signaling associated with apoptosis in chronic myelogenous leukemia cells.
Nam S; Williams A; Vultur A; List A; Bhalla K; Smith D; Lee FY; Jove R
Mol Cancer Ther; 2007 Apr; 6(4):1400-5. PubMed ID: 17431118
[TBL] [Abstract][Full Text] [Related]
17. Identification of New Shikonin Derivatives as Antitumor Agents Targeting STAT3 SH2 Domain.
Qiu HY; Zhu X; Luo YL; Lin HY; Tang CY; Qi JL; Pang YJ; Yang RW; Lu GH; Wang XM; Yang YH
Sci Rep; 2017 Jun; 7(1):2863. PubMed ID: 28588262
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of Bcr-Abl kinase activity by PD180970 blocks constitutive activation of Stat5 and growth of CML cells.
Huang M; Dorsey JF; Epling-Burnette PK; Nimmanapalli R; Landowski TH; Mora LB; Niu G; Sinibaldi D; Bai F; Kraker A; Yu H; Moscinski L; Wei S; Djeu J; Dalton WS; Bhalla K; Loughran TP; Wu J; Jove R
Oncogene; 2002 Dec; 21(57):8804-16. PubMed ID: 12483533
[TBL] [Abstract][Full Text] [Related]
19. Regulation of the interferon regulatory factor-8 (IRF-8) tumor suppressor gene by the signal transducer and activator of transcription 5 (STAT5) transcription factor in chronic myeloid leukemia.
Waight JD; Banik D; Griffiths EA; Nemeth MJ; Abrams SI
J Biol Chem; 2014 May; 289(22):15642-52. PubMed ID: 24753251
[TBL] [Abstract][Full Text] [Related]
20. Distinct roles of STAT3 and STAT5 in the pathogenesis and targeted therapy of breast cancer.
Walker SR; Xiang M; Frank DA
Mol Cell Endocrinol; 2014 Jan; 382(1):616-621. PubMed ID: 23531638
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
